A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Clinical trial NCT07215390 · RECRUITING
Trial details
- NCT number
- NCT07215390
- Sponsor
- Apellis Pharmaceuticals, Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-23
- Primary completion
- 2027-06-25
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.